Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2020 September;32(3) > Minerva Biotecnologica 2020 September;32(3):95-100

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Biotecnologica 2020 September;32(3):95-100

DOI: 10.23736/S1120-4826.20.02620-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Evaluation of the polymorphism NUDT15c.415C>T real-time PCR on the CFX96 real-time PCR system and 7500 real-time PCR system

Valentina DAPRÀ 1, 2, Ilaria GALLIANO 1, Carla ALLIAUDI 1, Elena ZANIOL 1, Elisa GRAZIANO 1, Cristina CALVI 1, Paola MONTANARI 1, Massimiliano BERGALLO 1, 2

1 Department of Public Health and Pediatrics, School of Medicine, University of Turin, Turin, Italy; 2 BioMole srl, Turin, Italy



BACKGROUND: Thiopurine-related hematoxicity is clinically relevant and therapy-limiting in treatment of patients with acute lymphoblastic leukemia (ALL) or inflammatory bowel disease (IBD). For clinical implementation, the Clinical Pharmacogenetics Implementation Consortium (CPIC ) published peer-reviewed and evidence-based gene/drug clinical practice guidelines indicating preemptive TPMT genotype-guided thiopurine-dose individualization to mitigate drug toxicity. Recently loss-of-function germline variants in NUDT15 have been identified as additional genetic determinants of thiopurine intolerance.
METHODS: We used a TaqMAMA genotyping PCR assay NUDT15-MAMAPCR real time cod. BioMole 020 for detection of c.415 C-to-T transition (rs116855232) variant of the nucleoside diphosphate-linked moiety X motif 15 (NUDT15) gene on 7500 Real-Time PCR System and CFX96 Real-Time PCR System. Subsequently we used this assay in subject with thiopurine treatment.
RESULTS: Homozygotes and heterozygotes condition were tested. We reported the ΔCt obtained from mimic homozygotes C/C (CtsC 22.31, CtaT 28.90 with ΔCt 6.59) and T/T (CtsT 22.75, CtaC 31.01 with ΔCt 8.26) and heterozygotes C/T conditions (CtsC 23.33, CtsT 23.72 with ΔCt 0.38). For the clinical validation of the techniques we analyzed a population of 31 thiopurine treated pediatric patients blood samples (13 male, 18 female). All 31 samples were tested with 31/31 (100%) homozygotes (31 CC ).
CONCLUSIONS: The CFX96 Real-Time PCR System is a suitable instrument to use in conjunction with the NUDT15-MAMAPCR real time to generate predictive information about genotyping assay of rs116855232, C415T polymorphism in children with thiopurine treatment.


KEY WORDS: Real-time polymerase chain reaction; Toxicity tests; Polymorphism, genetic

inizio pagina